Hepatitis News:
March 2006
Safety of nation's blood supply a prime concern for hemophiliacs
"The first people hurt when the nation's blood supply gets tainted are likely to
be those whose lives depend on transfusions."
HGSI's Albuferon for hepatitis C advancing
"Human Genome Sciences said its hepatitis C treatment Albuferon showed strong
anti-viral activity in phase 2 trials."
Hepatitis
C Epidemic Vastly Underestimated by UK Government
"There are more than double the number of people infected with the hepatitis C
virus (HCV) in England and Wales than the government has estimated, delegates at
the British Society of Gastroenterology's Annual Scientific Meeting were
warned."
Idenix says Hepatitis C clinical trial adjustments will lead to delay
"Idenix Pharmaceuticals Inc said it has modified an ongoing clinic trial for
Hepatitis C treatment valopicitabine (NM283) by reducing dosing levels from 800
mg per day to 200 mg per day or 400 mg per day due to dose-related
gastrointestinal side effects."
Clinical Study
Results of ActilonT for Hepatitis C
"Coley Pharmaceutical Group, Inc. announced positive top-line interim data from
the company's 12-week, randomized, controlled clinical study of ActilonT (CPG
10101) in combinations with pegylated interferon and/or ribavirin for the
treatment of chronic hepatitis C virus (HCV) in the relapsed subset of treatment
experienced patients."
Liver
Transplants & Hepatitis C
"Tens of thousands of people are infected with Hepatitis C each year, and most
of them won't even show any signs or symptoms of the disease. In the most severe
cases, Hepatitis C can cause the liver to fail, and the only way to survive is
with a transplant."
Researchers show
laboratory hepatitis C strain is also infectious in animal models
"An important step in developing a treatment for viral diseases is for
scientists to culture live viruses from infected patients, but the hepatitis C
virus (HCV), a major cause of chronic and sometimes fatal liver disease, has
proven to be particularly wily."
Novartis Seen 'Saving Face' With Idenix Hep C Deal
"Friedman, Billings, Ramsey reiterated an "outperform" rating on Idenix
Pharmaceuticals after Swiss pharmaceutical titan Novartis exercised an option to
co-develop the biotech firm's lead drug candidate."
Valeant
Announces Results of Phase 3 VISER 1 Trial of Viramidine versus Ribavirin
"Valeant Pharmaceuticals reported preliminary summary results this week of the
VISER 1 Phase 3 trial of Viramidine (taribavirin) versus ribavirin when both
drugs are administered in combination with peginterferon alfa-2b (PegIntron) in
treatment-naïve patients with chronic hepatitis C."
Treatment-related Depression Is the Most Significant Factor Affecting
Health-related Quality of Life in Chronic Hepatitis C
"Individuals with chronic hepatitis C who are treatment-naïve frequently
experience a diminishment of their health-related quality of life (HRQL)."
Clinical Trials, Cohort Studies, Pilot Studies
Portal Hypertensive Gastropathy in Chronic Hepatitis C Patients with Bridging
Fibrosis and Compensated Cirrhosis: Results from the HALT-C Trial. Fontana
RJ, et al. Am J Gastroenterol. 2006 Mar 30; [Epub ahead of print]
Significance of occult HBV infection in patients with chronic hepatitis C.
Anwar W, Sarwar M, Hussain AB, Tariq WU, Saif M. J Coll Physicians Surg Pak.
2006 Mar;16(3):192-5.
Mortality and causes of death in patients with hemophilia, 1992-2001: a
prospective cohort study.
Plug I, et al. J Thromb Haemost. 2006 Mar;4(3):510-6.
Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective
study. Foucher J, et al. Gut. 2006 Mar;55(3):403-8. Epub 2005 Jul 14.
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy
on sustained virologic response. Kamal SM, et al. Gastroenterology. 2006
Mar;130(3):632-8.
Interferon-alpha improves bone resorption and osteopenia in patients with
chronic hepatitis C.
Nishida N, Komatsu Y, Komeda T, Fukuda Y. Hepatol Res. 2006 Mar 1; [Epub ahead
of print]
Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy
on sustained virologic response. Kamal SM, et al. Gastroenterology. 2006
Mar;130(3):632-8.
Management of Hepatitis C Disease Among VA Patients With Schizophrenia and
Substance Use Disorders.
Huckans MS, Blackwell AD, Harms TA, Hauser P. Psychiatr Serv. 2006
Mar;57(3):403-6.
Peginterferon Alfa-2a plus Ribavirin for Initial Treatment of Chronic Hepatitis
C in Korea. Lee H, et al. Korean J Hepatol. 2006 Mar;12(1):31-40.
Intrahepatic cholestasis of pregnancy as an indicator of liver and biliary
diseases: A population-based study.
Ropponen A, Sund R, Riikonen S, Ylikorkala O, Aittomaki K. Hepatology. 2006
Apr;43(4):723-8.
Declining sustained virological response in hepatitis C. Batool U, Qureshi
S. J Coll Physicians Surg Pak. 2006 Mar;16(3):187-91.
Effects of fatty liver and related factors on the efficacy of combination
antiviral therapy in patients with chronic hepatitis C. Jian Wu Y, Shu Chen
L, Gui Qiang W. Liver Int. 2006 Mar;26(2):166-72.
Autoimmune thrombocytopenia in response to splenectomy in cirrhotic patients
with accompanying hepatitis C. Sekiguchi T, Nagamine T, Takagi H, Mori M.
World J Gastroenterol. 2006 Feb 28;12(8):1205-10.
Effect of HCV infection on hepatic fibrosis in patients of thalassaemia major.
Anwar M, et al. J Coll Physicians Surg Pak. 2006 Mar;16(3):200-3.
Sustained virological response rates and health-related quality of life after
interferon and ribavirin therapy in patients with chronic hepatitis C virus
infection and persistently normal alanine aminotransferase levels. Bini EJ,
Mehandru S. Aliment Pharmacol Ther. 2006 Mar 15;23(6):777-85.
Hepatitis C infection in hemodialysis patients: protective against oxidative
stress? Sezer S, et al. Transplant Proc. 2006 Mar;38(2):406-10.
Correlates of hepatitis C virus (HCV) RNA negativity among HCV-seropositive
blood donors. Busch MP, et al. Transfusion. 2006 Mar;46(3):469-75.
Hepatic steatosis is a predictor of poor response to interferon alpha-2b and
ribavirin combination therapy in Japanese patients with chronic hepatitis C.
Yaginuma R, et al. Hepatol Res. 2006 Mar 10; [Epub ahead of print]
Relationship between Hepatitis C and Chronic Kidney Disease: Results from the
Third National Health and Nutrition Examination Survey. Tsui JI, et al. J Am
Soc Nephrol. 2006 Apr;17(4):1168-74. Epub 2006 Mar 8.
Hepatitis C virus free-virion and immune-complex dynamics during interferon
therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
Fujita N, et al. J Viral Hepat. 2006 Mar;13(3):190-8.
A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b
and ribavirin combination in patients with chronic hepatitis C using biochemical
markers. d'Arondel C, et al. J Viral Hepat. 2006 Mar;13(3):182-9.
Intrahepatic hepatitis C virus replication correlates with chronic hepatitis C
disease severity in vivo. Pal S, et al. J Virol. 2006 Mar;80(5):2280-90.
Twenty-four hour kinetics of hepatitis C virus and antiviral effect of
alpha-interferon. Boulestin A, et al. J Med Virol. 2006 Mar;78(3):365-71.
Basic And Applied Science, Pre-Clinical Studies
Analysis of mutations within the 5' untranslated region, interferon sensitivity
region, and PePHD region as a function of response to interferon therapy in
hepatitis C virus-infected patients in India. Gupta R, et al. J Clin
Microbiol. 2006 Mar;44(3):709-15.
The NS5A protein of HCV genotype 1a is cleaved by caspases to produce C-terminal
truncated forms of the protein that reside mainly in the cytosol. Kalamvoki
M, Georgopoulou U, Mavromara P. J Biol Chem. 2006 Mar 3; [Epub ahead of print]
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis
C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis. Koch U,
et al. J Med Chem. 2006 Mar 9;49(5):1693-705.
Subcellular localization of hepatitis C virus structural proteins in a cell
culture system that efficiently replicates the virus. Rouille Y, et al. J
Virol. 2006 Mar;80(6):2832-41.
Preclinical evaluation of two neutralizing human monoclonal antibodies against
hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in
liver transplant patients. Eren R, et al. J Virol. 2006 Mar;80(6):2654-64.
Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted
drug delivery. Brookes S, et al. Bioconjug Chem. 2006 Mar-Apr;17(2):530-7.
Inhibition of hepatitis C virus RNA replication by short hairpin RNA synthesized
by T7 RNA polymerase in hepatitis C virus subgenomic replicons. Hamazaki H,
et al. Biochem Biophys Res Commun. 2006 Mar 25; [Epub ahead of print]
Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors,
cyclosporin A, and NIM811. Goto K, et al. Biochem Biophys Res Commun. 2006
Mar 24; [Epub ahead of print]
Initiation factor-independent translation mediated by the hepatitis C virus
internal ribosome entry site. Lancaster AM, Jan E, Sarnow P. RNA. 2006 Mar
23; [Epub ahead of print]
Recombinant virus-like particles as a carrier of B- and T-cell epitopes of
hepatitis C virus (HCV). Mihailova M, et al. Vaccine. 2006 Mar 15; [Epub
ahead of print]
HLA-C and KIR Genes in Hepatitis C Virus Infection. Montes-Cano MA, et al.
Hum Immunol. 2005 Nov;66(11):1106-9. Epub 2006 Mar 9.
Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based
antiviral response. Wang Y, et al. Gastroenterology. 2006 Mar;130(3):883-92.
Src homology 3 domain of hepatitis C virus NS5A protein interacts with Bin1 and
is important for apoptosis and infectivity. Nanda SK, Herion D, Liang TJ.
Gastroenterology. 2006 Mar;130(3):794-809.
Distinct toll-like receptor expression in monocytes and T cells in chronic HCV
infection. Dolganiuc A, Garcia C, Kodys K, Szabo G. World J Gastroenterol.
2006 Feb 28;12(8):1198-204.
The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice
are resistant to lethal tumour- necrosis factor-a-mediated liver disease.
Frelin L, et al. Gut. 2006 Mar 9; [Epub ahead of print]
The relationship between hepatic immunoglobulin production and CD154 expression
in chronic liver diseases. Mayo MJ, et al. Liver Int. 2006 Mar;26(2):187-96.
Discriminant function based on hyaluronic acid and its degrading enzymes and
degradation products for differentiating cirrhotic from non-cirrhotic liver
diseased patients in chronic HCV infection.
Attallah AM, et al. Clin Chim Acta. 2006 Mar 15; [Epub ahead of print]
S-adenosylmethionine and betaine correct hepatitis C virus induced inhibition of
interferon signaling in vitro. Duong FH, et al. Hepatology. 2006 Mar
23;43(4):796-806 [Epub ahead of print]
Microarray analyses and molecular profiling of Stat3 signaling pathway induced
by hepatitis C virus core protein in human hepatocytes. Basu A, et al.
Virology. 2006 Mar 16; [Epub ahead of print]
Epigenetic silencing of interferon-inducible genes is implicated in interferon
resistance of hepatitis C virus replicon-harboring cells. Naka K, et al. J
Hepatol. 2006 Feb 28; [Epub ahead of print]
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of
hepatitis C virus replication in vitro. Paeshuyse J, et al. Hepatology. 2006
Mar 23;43(4):761-770 [Epub ahead of print]
HIV/HCV Coinfection
Gene Expression Profiles in Hepatitis C Virus (HCV) and HIV Coinfection: Class
Prediction Analyses before Treatment Predict the Outcome of Anti-HCV Therapy
among HIV-Coinfected Persons. Lempicki RA, et al.
J Infect Dis. 2006 Apr 15;193(8):1172-7. Epub 2006 Mar 13.
Antiretroviral use and other risks for HIV-associated neuropathies in an
international cohort. Cherry CL, et al. Neurology. 2006 Mar 28;66(6):867-73.
Changes in the distribution of hepatitis C virus (HCV) genotypes over time in
Spain according to HIV serostatus: Implications for HCV therapy in
HCV/HIV-coinfected patients. Ramos B, et al. J Infect. 2006 Mar 25; [Epub
ahead of print]
Sustained virologic response with short-course ribavirin and peginterferon
treatment in 2 patients coinfected with HIV and HCV genotype 1. Patel MR,
Mullen MP, Dieterich DT. AIDS Read. 2006 Mar;16(3):164, 168-9; discussion 168-9.
Complementary And Alternative Therapies
Triple therapy of interferon and ribavirin with zinc supplementation for
patients with chronic hepatitis C: A randomized controlled clinical trial.
Suzuki H, et al. World J Gastroenterol. 2006 Feb 28;12(8):1265-9
Miscellaneous Works
Epidemiological, biological and histological characterization of patients with
indeterminate third-generation recombinant immunoblot assay antibody results for
hepatitis C virus. Rios M, et al. J Viral Hepat. 2006 Mar;13(3):177-81.
Psychological impact of chronic hepatitis C: Comparison with other stressful
life events and chronic diseases.
Castera L, et al. World J Gastroenterol. 2006 Mar 14;12(10):1545-1550.
Comparison of conventional PCR with real-time PCR and branched DNA-based assays
for hepatitis C virus RNA quantification and clinical significance for genotypes
1 to 5. Sarrazin C, et al. J Clin Microbiol. 2006 Mar;44(3):729-37.
Independent prospective multicenter validation of biochemical markers
(fibrotest-actitest) for the prediction of liver fibrosis and activity in
patients with chronic hepatitis C: the fibropaca study. Halfon P, et al. Am
J Gastroenterol. 2006 Mar;101(3):547-55.
|
